News

The National Organization for Rare Disorders (NORD) is seeking individuals willing to share real-life experiences with rare diseases to speak at its upcoming virtual Living Rare, Living Stronger NORD Patient and Family Forum. The interactive, patient-focused forum will be held online June 26-27. The deadline to apply for…

Using multiple warming measures, hypothermia was prevented in an adult man with severe cold agglutinin disease (CAD) undergoing surgery, a recent case study reports. According to the investigators, the report is the first to describe the success of a combination of…

Off-label treatment with Imbruvica (ibrutinib), a lymphoma and leukemia therapy, can reduce the anemia and peripheral symptoms of cold agglutinin disease (CAD), a preliminary study has found. The study, “Effective Treatment of Cold Agglutinin Disease/Cold…

Use of the investigational therapy sutimlimab results in substantial reductions in patient hospitalizations and blood transfusions among adults with primary cold agglutinin disease (CAD), a post hoc analysis of the CARDINAL trial found. The results of the analysis point…

Cold agglutinin disease (CAD) disease negatively affects a variety of aspects of daily living, with patients often experiencing fatigue, according to new research. In a separate study, it was found that CAD patients appear to be at an increased risk of anxiety or depression. Researchers from Sanofi…

To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) has launched an initiative across the U.S. Its goal is to establish a Rare Disease Advisory Council (RDAC)…

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a survey conducted by Eurordis-Rare Diseases Europe. “People living with rare diseases in Europe have found themselves caught as collateral…

The U.S. Food and Drug Administration (FDA) has issued a complete response to Sanofi’s application requesting that its investigational therapy sutimlimab be approved for treating hemolysis — the breakdown of red blood cells — in adults with cold agglutinin disease (CAD), the company announced in…

Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how their respective organizations came to be, as well as the benefits of creating patient registries and how they can help…

People with non-Hodgkin’s lymphoma (NHL) — a type of blood cancer — that co-occurs with autoimmune hemolytic anemia (AIHA) have a poor prognosis, suggesting a need for further research into this rare combination of conditions, a case report highlights. The case was reported at the 2020 Lymphoma,…